Olanzapine: A pharmacoeconomic review of its use in schizophrenia

PharmacoEconomics

Volumn 15, Issue 6, 1999, Pages 611-640

  Foster, Rachel H ^a   Goa, Karen L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

HALOPERIDOL; NEUROLEPTIC AGENT; OLANZAPINE; RISPERIDONE;

ARTICLE; DATA BASE; DRUG COST; DRUG EFFICACY; DRUG TOLERABILITY; EXTRAPYRAMIDAL SYMPTOM; HEALTH CARE COST; HUMAN; MEDICAL ASSESSMENT; PRIORITY JOURNAL; QUALITY OF LIFE; SCHIZOPHRENIA;

ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; COSTS AND COST ANALYSIS; DYSKINESIA, DRUG-INDUCED; HUMANS; PIRENZEPINE; QUALITY OF LIFE; SCHIZOPHRENIA;

EID: 0033032922     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-199915060-00008     Document Type: Article

References (122)

1. 1. Lehman AF, Steinwachs DM, Co-Investigators of the PORTP. At issue: translating research into practice: the Schizophrenia Outcomes Research Team (PORT) treatment recommendations. Schizophr Bull 1498; 24 (1): 1-10
2. 2. American Psychiatric Association. Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 1997 Apr; 154 (4 Suppl): 1-63
3. 3. Waddington JL, O'Callaghan E. What makes an antipsychotic 'atypical'. CNS Drugs 1997 May; 7 (5): 341-6
4. 4. Diagnostic and statistical manual of mental disorders: DSMIV. 4th ed. Washington, DC: American Psychiatric Association, 1994
5. 5. Jones P, Cannon M. The new epidemiology of schizophrenia. Psychiatr Clin North Am 1998 Mar; 21 (1): 1-25
6. 6. Awad AG, Voruganti LNP, Heslegrave RJ. Measuring quality of life in patients with schizophrenia. Pharmacoeconomics 1997 Jan; 11: 32-47
7. 7. Harris EC, Barraclough B. Excess mortality of mental disorder. Br J Psychiatry 1998 Jul; 173: 11-53
8. 8. Brown S. Excess mortality of schizophrenia: a meta-analysis. Br J Psychiatry 1997 Dec; 171: 502-8
9. 9. Collaborative Working Group on Clinical Trial Evaluations. Atypical antipsychotics for treatment of depression in schizophrenia and affective disorders. J Clin Psychiatry 1998; 59 Suppl. 12: 41-5
10. 10. Lindström E. The hidden cost of schizophrenia. J Drug Dev Clin Pract 1996 Jan; 7: 281-8
11. 11. Capri S. Methods for evaluation of the direct and indirect costs of long term schizophrenia. Acta Psychiatr Scand 1994; 89 Suppl. 382: 80-3
12. 12. Andreasen NC. Assessment issues and the cost of schizophrenia. Schizophr Bull 1991; 17: 475-81
13. 13. Rupp A, Keith SJ. The costs of schizophrenia: assessing the burden. Psychiatr Clin North Am 1993 Jun; 16: 413-23
14. 14. Frankenburg FR, Hegarty JD. Cost considerations in the treatment of schizophrenia. CNS Drugs 1996 Jan; 5: 75-82
15. 15. Weiden PJ, Olfson M. Cost of relapse in schizophrenia. Schizophr Bull 1995; 21 (3): 419-29
16. 16. Knapp M, Kavanagh S. Economic outcomes and costs in the treatment of schizophrenia. Clin Ther 1997 Jan-Feb; 19: 128-38
17. 17. Terkelsen KG, Menikoff A. Measuring the costs of schizophrenia: implications for the post-institutional era in the US. Pharmacoeconomics 1995 Sep; 8: 199-222
18. 18. Glazer WM, Johnstone BM. Pharmacoeconomic evaluation of antipsychotic therapy for schizophrenia. J Clin Psychiatry 1997; 58 Suppl. 10: 50-4
19. 19. Scottish Schizophrenia Research Group. The Scottish first episode schizophrenia study VIII. Five-year follow-up: clinical and psychosocial findings. Br J Psychiatry 1992; 161: 496-500
20. 20. Daniels BA, Kirkby KC, Hay DA, et al. Predictability of rehospitalisation over 5 years for schizophrenia, bipolar disorder and depression. Aust N Z J Psychiatry 1998 Apr; 32: 281-6
21. 21. Elbelt U, Muller P, Schaefer E. Occupational integration of schizophrenic patients under current treatment conditions [in German]. Psychiatr Prax 1998 Jan; 25: 33-7
22. 22. Knapp M. Costs of schizophrenia. Br J Psychiatry 1997 Dec; 171: 509-18
23. 23. Genduso LA, Haley JC. Cost of illness studies for schizophrenia: components, benefits, results, and implications. Am J Manage Care 1997 Jun; 3: 873-7
24. 24. Wasylenki DA. The cost of schizophrenia. Can J Psychiatry 1994 Nov; 39 Suppl. 2: 65-9
25. 25. National Advisory Mental Health Council. Health care reform for Americans with severe mental illnesses: report of the National Advisory Mental Health Council. Am J Psychiatry 1993 Oct; 150: 1447-65
26. 26. Rice DP, Kelman S, Miller LS. The economic burden of mental illness. Hosp Community Psychiatry 1992 Dec; 43 (12): 1227-32
27. 27. Rouillon F, Toumi M, Dansette G-Y, et al. Some aspects of the cost of schizophrenia in France. Pharmacoeconomics 1997 Jun; 11: 578-94
28. 28. Evers SM, Ament AJ. Costs of schizophrenia in The Netherlands, Schizophr Bull 1995; 21: 141-53
29. 29. De Hert M, Thys E, Boydens J, et al. Health care expenditure on schizophrenia patients in Belgium. Schizophr Bull 1998; 24 (4): 519-27
30. 30. Davies LM, Drummond MF. Economics and schizophrenia: the real cost. Br J Psychiatry 1994 Nov; 165 Suppl. 25: 18-21
31. 31. Suleiman TG, Ohaeri JU, Lawal RA, et al. Financial cost of treating out-patients with schizophrenia in Nigeria. Br J Psychiatry 1997 Oct; 171: 364-8
32. 32. Rice DP, Miller LS. The economic burden of schizophrenia. Presented at the Sixth Biennial Conference on the Economics of Mental Health; 1992 Sep 21-22; Bethesda (MD), USA
33. 33. Wyatt RJ, Henter I, Leary MC, et al. An economic evaluation of schizophrenia-1991. Soc Psychiatry Psychiatr Epidemiol 1995; 30: 196-205
34. 34. Rice DP, Miller LS. Health economics and cost implications of anxiety and other mental disorders in the United States. Br J Psychiatry 1998 Jul; 173 Suppl. 34: 4-9
35. 35. Langley-Hawthorne C. Modeling the lifetime costs of treating schizophrenia in Australia. Clin Ther 1997 Nov-Dec; 19: 1470-95
36. 36. Fulton B, Goa KL. Olanzapine: a review of its pharmacological properties and therapeutic efficacy in the management of schizophrenia and related psychoses. Drugs 1997 Feb; 53: 281-98
37. 37. Beasley Jr CM, Tollefson G, Tran P. Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 1996 Feb; 14: 111-23
38. 38. Beasley Jr CM, Hamilton SH, Crawford AM, et al. Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial. Eur Neuropsychopharmacol 1997 May; 7: 125-37
39. 39. Beasley Jr CM, Sanger T, Satterlee W. Olanzapine versus placebo: results of a double-blind, fixed dose olanzapine trial. Psychopharmacology 1996 Mar; 124: 159-67
40. 40. Nemeroff CB. Dosing the antipsychotic medication olanzapine. J Clin Psychiatry 1997; 58 Suppl. 10: 45-9
41. 41. Tran PV, Hamilton SH, Kuntz AJ, et al. Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders. J Clin Psychopharmacol 1997 Oct; 17: 407-18
42. 42. Tollefson GD, Beasley Jr CM, Tran PV, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am J Psychiatry 1997 Apr; 154: 457-65
43. 43. Diagnostic and statistical manual of mental disorders: DSM-III-R. 3rd revised ed. Washington, DC: American Psychiatric Association, 1987
44. 44. Sanger TM, Lieberman JA, Tohen M, et al. Olanzapine versus haloperidol treatment in first-episode psychosis. Am J Psychiatry 1999 Jan; 156 (1): 79-87
45. 45. Tran PV, Dellva MA, Tollefson GD, et al. Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia. J Clin Psychiatry 1997 May; 58: 205-11
46. 46. Gureje O. Olanzapine versus risperidone in the treatment of schizophrenia and related psychotic disorders [abstract]. XXIst CINP Congress; 1998 Jul 12-16; Glasgow, Scotland
47. 47. Gureje O, Miles W, Keks N, et al. Olanzapine versus risperidone in the management of schizophrenia: a randomized double-blind trial in Australia and New Zealand. Eli Lilly (Indianapolis); Feb 1999 (Data on file)
48. 48. Conley RR, Brecher M, Risperidone/Olanzapine Study Group. Risperidone versus olanzapine in patients with schizophrenia or schizoaffective disorder. Presented at the 11th Annual Congress of the European College of Neuropsychopharmacologyr; 1998 Oct 31 -Nov 4; Paris, France
49. 49. Tran P, Shamir E, Poyorovski M, et al. Olanzapine in the treatment of patients who failed to respond to or tolerate clozapine [abstract]. Psychopharmacol Bull 1997; 33 (3): 599
50. 50. Thomas SG, Labbate LA. Management of treatment-resistant schizophrenia with olanzapine [letter]. Can J Psychiatry 1998 Mar; 43: 195-6
51. 51. Dursun SM, Bird D, Flinn J. Olanzapine in treatment-resistant schizophrenia patients: preliminary results from an open prospective study [abstract]. Br J Clin Pharmacol 1998 Sep; 46: 301P-2P
52. 52. Baldacchino AM, Stubbs JH, Nevison-Andrews D. The use of olanzapine in non-compliant or treatment-resistant clozapine populations in hospital. Pharm J 1998 Feb 7; 260: 207-9
53. 53. Martín J, Gómez J-C, García-Bernardo E, et al. Olanzapine in treatment-refractory schizophrenia: results of an open-label study. J Clin Psychiatry 1997 Nov; 58: 479-83
54. 54. Conley RR, Tamminga CA, Bartko JJ, et al. Olanzapine compared with chlorpromazine in treatment-resistant schizophrenia. Am J Psychiatry 1998 Jul; 155: 914-20
55. 55. Sanders RD, Mossman D. An open trial of olanzapine in patients with treatment-refractory psychoses. J Clin Psychopharmacol 1999; 19 (1): 62-6
56. 56. Benzen JN. Birken M, Kiesler G, et al. Olanzapine vs. clozapine in resistant schizophrenic patients - results of an international double-blind randomised clinical trial [abstract]. XXIst CINP Congress; 1998 Jul 12-16; Glasgow, Scotland
57. 57. Obenchain RL, Johnstone BM. Mixed-model imputation of cost data for early discontinuers from a randomized clinical trial. Drug Info J 1999; 33: 191-209
58. 58. Buchanan RW, Gold JM. Negative symptoms: diagnosis, treatment and prognosis. Int Clin Psychopharmacol 1996; 11 Suppl. 2: 3-11
59. 59. Keefe RSE, Mohs RC, Losonczy MF, et al. Characteristics of very poor outcome schizophrenia. Am J Psychiatry 1987 Jul; 144 (7): 889-95
60. 60. Tollefson GD, Sanger TM. Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry 1997 Apr; 154: 466-74
61. 61. Tollefson GD, Sanger TM, Lu Y, et al. Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol. Arch Gen Psychiatry 1991S Mar; 55: 250-8
62. 62. Tran PV, Tollefson GD, Sunger TM, et al. Olanzapine versus haloperidol in the treatment of schizoaffective disorder: acute and long term therapy. Br J Psychiatry 1999; 174: 15-22
63. 61 Tollefson GD, Sanger TM, Beasley CM, et al. A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia. Biol Psychiatry 1998 Jun 1; 43: 803-10
64. 64. Sevy S, Davidson M. The cost of cognitive impairment in schizophrenia. Schizophr Res 1995 Sep; 17: 1-3
65. 65. Canadian Cognition and Outcome Study Group. Neuropsychological change in early phase schizophrenia over twelve months of treatment with olanzapine, risperidone or haloperidol [abstract]. Schizophr Res 1998; 29 (1-2): 152-3
66. 66. Noordsy DL, O'Keele C. Effectiveness of combining atypical antipsychotics and psychosocial rehabilitation in a CMHC selling. J Clin Psychiatry. In press
67. 67. Gilbert PL, Harris J, McAdams LA, et al. Neuroleptic withdrawal in schizophrenic patients: a review of the literature. Arch Gen Psychiatry 1995 May; 52: 173-88
68. 68. Dellva MA, Tran P, Tollefson GD. Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia. Psychiatr Serv 1997 Dec; 48: 1571-57
69. 69. Tran PV, Dellva MA, Tollefson GD, et al. Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses. Br J Psychiatry 1998 Jun; 172: 499-505
70. 70. Hamilton SH, Genduso LA, Revicki DA. Medical resource use and work and social outcomes for olanzapine compared with haloperidol in the treatment of schizophrenia und other psychotic disorders. Presented at the 9th Biennial Winter Workshop on Schizophrenia; 1998 Feb 7-13; Davos, Switzerland
71. 71. Fleischhacker WW, Meise U, Günther V, et al. Compliance with antipsychotic drug treatment: influence of side effects. Acta Psychiatr Scand 1994; 89 Suppl. 382: 11-5
72. 72. Van Putten T. Why do schizophrenic patients refuse to take their drugs? Arch Gen Psychiatry 1974 Jul; 31: 67-72
73. 73. Keks NA. Minimizing the non-extrapyramidal side-effects of antipsychotics. Acta Psychiatr Scand 1996; 94: 18-24
74. 74. Beasley Jr CM, Tollefson GD, Tran PV. Safety of olanzapine. J Clin Psychiatry 1997; 58 Suppl 10: 13-7
75. 75. Foster RH, Goa KL. Risperidone: a pharmacoeconomic review of its use in schizophrenia. Pharmacoeconomics 1998 Jul; 14: 97-133
76. 76. Schooler NR. Comments on article by Tran and colleagues, double-blind comparison of olanzapine versus risperidone in treatment of schizophrenia and other psychotic disorders [letter]. J Clin Psychopharmacol 1998 Apr; 18: 174-5
77. 77. Gheuens J, Grebb JA. Comments on article by Tran and associates, double-blind comparison of olanzapine versus risperidone in treatment of schizophrenia and other psychotic disorders [letter]. J Clin Psychopharmacol 1998 Apr; 18: 176-7
78. 78. Tollefson GD, Tran PV. Comments on article by Tran and colleagues, double-blind comparison of olanzapine versus risperidone in treatment of schizophrenia an other psychotic disorders. Reply [letter]. J Clin Psychopharmacol 1998 Apr; 18: 175-6
79. 79. Tollefson GD, Tran PV. Comments on article by Tran and associates, double-blind comparison of olanzapine versus risperidone in treatment of schizophrenia and psychotic disorders. Reply [letter]. J Clin Psychopharmacol 1998 Apr; 18: 177-9
80. 80. Tollefson GD, Beasley Jr CM, Tamura RN, et al. Blind, controlled, long term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol. Am J Psychiatry 1997 Sep; 154: 1248-54
81. 81. Beasley CM, Dellva MA, Tamura RN, et al. Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long term treatment with olanzapine or haloperidol. Br J Psychiatry 1999; 174: 23-30
82. 82. Crawford AMK, Beasley Jr CM, Tollefson GD. The acute and long term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophr Res 1997 Jul 25; 26: 41-54
83. 83. Casey DE. Side effect profiles of new antipsychotic agents. J Clin Psychiatry 1996; 57 Suppl 11: 40-5
84. 84. Ho B-C, Nopoulos P, Flaum M, et al. Two-year outcome in first-episode schizophrenia: predictive value of symptoms for quality of life. Am J Psychiatry 1998 Sep; 155: 1196-201
85. 85. Browne S, Caravan J, Gervin M, et al. Quality of life in schizophrenia: insight anil subjective response to neuroleptics. J Nerv Ment Dis 1998 Feb; 186: 74-8
86. 86. Tunis SL, Croghan TW, Heilman DK, et al. Reliability, validity and application of the Medical Outcomes Study 36-Item Short Form Health Survey (SF 36) in schizophrenic patients treated with olanzapine versus haloperidol. Med Care. In press
87. 87. Dickerson FB, Ringel NB, Parente F. Subjective quality of life in outpatients with schizophrenia: clinical and utilization correlates. Acta Psychiatr Scand 1998 Aug; 98: 124-7
88. 88. Tunis SL, Croghan TW, Heilman DK, et al. Changes in perceived physical and mental health status of a schizophrenic patient population following initiation of a conventional or an atypical antipsychotic medication. Presented at the 151st Annual Meeting of the American Psychiatric Association; 1998 May 30-Jun 4; Toronto, Canada
89. 89. Hamilton SH, Revicki DA, Genduso LA, et al. Olanzapine versus placebo and haloperidol: quality of life and efficacy results of the North American double-blind trial. Neuropsychopharmacology 1998 Jan; 18: 41-9
90. 90. Revicki DA, Genduso LA, Hamilton SH, et al. Olanzapine versus haloperidol in the treatment of schizophrenia and other related disorders: quality of life and clinical outcomes of a randomized clinical trial. Qual Life Res. In press
91. 91. Heinrichs DW, Hanlon TE, Carpenter Jr WT. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984; 10: 388-98
92. 92. Revicki DA, Murray M. Assessing health-related quality of life outcomes of drug treatments for psychiatric disorders. CNS Drugs 1994 Jun; 1: 465-76
93. 93. Russo J, Trujillo CA, Wingerson D, et al. The MOS 36-Item Short Form Health Survey: reliability, validity, and preliminary findings in schizophrenic outpatients. Med Care 1998 May; 36: 752-6
94. 94. Revicki DA. Methods of pharmacoeconomic evaluation of psychopharmacologic therapies for patients with schizophrenia. J Psychiatry Neurosci 1997 Jul; 22: 256-66
95. 95. Glazer WM. Formulary decisions and health economics. J Clin Psychiatry 1998; 59 Suppl. 19: 23-9
96. 96. Hamilton SH, Revicki DA, Genduso LA, et al. Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia: results from a randomized clinical trial. Pharmacoeconomics 1999 May; 15 (5): 469-80
97. 97. Palmer CS, Revicki DA, Genduso LS, et al. A cost-effectiveness clinical decision analysis model for schizophrenia. Am J Manage Care 1998 Mar; 4 (3): 345-55
98. 98. Almond S, O'Donnell O. Cost analysis of the treatment of schizophrenia in the UK: a comparison of olanzapine and haloperidol. Pharmacoeconomics 1998 May; 13 (Pt 2): 575-88
99. 99. Sacristan JA, Gomez JC, Salvador-Carulla L. Análisis costeeffectividad de olanzapina frente a haloperidol en el tratamiento de la esquizofrenia en Espan̄a [in Spanish]. Actas Luso Esp Neurol Psiquiatr Cienc Aftnes 1997 JuI-Aug; 25: 225-34
100. 100. Grainger DL, Edgell ET, Andersen SW, et al. Resource use and quality of life of olanzapine compared with risperidone: results from an international randomized clinical trial [poster]. 11th Annual Congress of the European College of Neuropsychopharmacology; 1998 Oct; Paris, France
101. 101. Johnstone BM, Obenchain RL, Tunis SL, et al. Intent-to-treat analysis of repeated measures data from a randomized clinical trial comparing the cost and effectiveness of treatment for schizophrenia wilh olanzapine or haloperidol [poster]. 151st Annual Meeting of the American Psychiatric Association; 1998 May 30-Jun 4; Toronto, Canada
102. 102. Post HA, van Hout BA. Cost effectiveness of olanzapine in comparison to risperidone and haloperidol [abstract]. 13th ISTAHC 1997 May 25: 134
103. 103. Spannheimer A, Clouth J. Pharmacoeconomic evaluation of the treatment of schizophrenia in Germany: a comparison of olanzapine and haloperidol. Eli Lilly and Company (Indianapolis); 1999 (Data on file)
104. 104. Taylor D, Drummond S, Pendlebury J. Olanzapine in practice. Psychiatr Bull 1998; 22: 552-4
105. 105. Kasper S. Risperidone and olanzapine: optimal dosing for efficacy and tolerability in patients with schizophrenia. Int Clin Psychopharmacol 1998; 13 (6): 253-62
106. 106. Voris JC, Glazer WM. Use of risperidone and olanzapine in outpatient clinics at six Veterans Affairs hospitals. Psychiatr Serv 1999 Feb; 50 (2): 163-8
107. 107. Sheldon TA. Problems of using modelling in the economic evaluation of health care. Health Econ 1996; 5: 1-11
108. 108. Chan YC, Votolato NA, Nasrallab HA. Pharmacoeconomic comparisons of risperidone and olanzapine during acute inpatient treatment of schizophrenia [poster]. 36th Annual Meeting of the American College of Neuropsychopharmacology; 1997 Dec K-12; Waikoloa, Hawaii
109. 109. Procyshyn RM, Zerjav S. Drug utilization patterns and outcomes associated with in-hospital treatment with risperidone and olanzapine. Clin Ther 1998; 20 (6): 1203-17
110. 110. Love RC, Conley RR, Kelly DL, et al. Risperidone dosing trends in the Maryland state mental health system. Presented at the 36th Annual Meeting of the American College of Neuropsychoparmacology; Dec 8-12; Kamuela, Hawaii
111. 111. Sacristán JA, Gómez JC, Martín J. Pharmacoeconomic assessment of olanzapine in the treatment of refractory schizophrenia based on a pilot clinical study. Clin Drug Invest 1998 Jan; 15: 29-35
112. 112. Weiss MA, MeCollum M. Cost impact of using olanzapine at a Veterans Affairs Medical Center [abstract]. Value Health 1998 May-Jun; 1: 25
113. 113. "Rationing" of clozapine and risperidone. Pharm J 1996 Apr 13; 256: 513
114. 114. Maidment I. Atypical antipsychotics how not to market a medicine. Pharm J 1998 Nov 14; 261: 778
115. 115. Oregon Health Resources Commission. Preliminary medical technology assessment and health resources plan with recommended clinical practice guidelines for antipsychotic drugs [online]. Oregon Health Resources Commission. Available from URL http://ohppr.das.state.or.us/hrc/hrcadtap.htm [accessed 1999 Feb 1]
116. 116. Buckley PF. Treatment of schizophrenia: let's talk dollars and sense. Am J Manage Care 1998 Mar; 4: 369-83
117. 117. Loebel AD, Botts SR, Feldman BI. Atypical antipsychotics in the managed care era. Am J Manage Care 1998 Jan; 4 Suppl.: 37-58
118. 118. Johnstone BM, Loosbrock DL, Russo PA, et al. The Schizophrenia Care and Assessment Program: prospective measurement of therapeutic outcomes using an observational design. Eli Lilly (Indianapolis); 1999 (Data on file)
119. 119. Haley JC, Russo PA, Johnstone BM, et al. Prospective, naturalistic outcomes measurement: the Schizophrenia Care and Assessment Program (SCAP). Value Health 1998 May-Jun; 1 (1): 89
120. 120. Glazer WM, Ereshefsky L. A pharmacoeconomic model of outpatient antipsychotic therapy in "revolving door" schizophrenic patients. J Clin Psychiatry 1996 Aug; 57 (8): 337-45
121. 121. Maynard A, Bloor K. Building castles on sands or quicksands? The strengths and weaknesses of economic evaluation in pharmaceuticals. Br J Psychiatry 1998 Sep; 173 Suppl. 36: 12-8
122. 122. Risperdal vs Zyprexa battle rages on. Scrip 1998 Nov 6; 2385: 21